Drug
Larotrectinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | TRK targeting TKI |
| Mechanism of Action | Pan-TRK inhibitor |
| Half-life | 3 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Uncertain/possibly no radiosensitization (TrkA inhibition was radioprotective in some models) (Jarboe et al., Radiotherapy and Oncology, 2012; Hassiepen et al., Cancers, 2021), though evidence is limited.
Data on this page refer exclusively to patients treated with
Larotrectinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
TRK targeting TKI group page.